| Contrast-Enhanced [(18)F]fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography for Staging and Radiotherapy Planning in Patients With Anal Cancer. | |
| | |
MedLine Citation:
|
PMID: 20832181 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
PURPOSE: The practice of surgical staging and treatment of anal cancer has been replaced by noninvasive staging and combined modality therapy. For appropriate patient management, accurate lymph node staging is crucial. The present study evaluated the feasibility and diagnostic accuracy of contrast-enhanced [(18)F]fluoro-2-deoxy-d-glucose ([(18)F]FDG)-positron emission tomography/computed tomography (PET/CT) for staging and radiotherapy planning of anal cancer. METHODS AND MATERIALS: A total of 22 consecutive patients (median age, 61 years old) with anal cancer underwent complete staging evaluation including physical examination, biopsy of the primary tumor, and contrast-enhanced (ce)-PET/CT. Patients were positioned as they would be for their subsequent radiotherapy. PET and CT images were evaluated independently for detectability and localization of the primary tumor, pelvic and inguinal lymph nodes, and distant metastasis. The stage, determined by CT or PET alone, and the proposed therapy planning were compared with the stage and management determined by ce-PET/CT. Data from ce-PET/CT were used for radiotherapy planning. RESULTS: ce-PET/CT revealed locoregional lymph node metastasis in 11 of 22 patients (50%). After simultaneous reading of PET and CT data sets by experienced observers, 3 patients (14%) were found to have sites of disease not seen on CT that were identified on PET. Two patients had sites of disease not seen on PET that were identified on CT. In summary, 2 patients were upstaged, and 4 patients were downstaged due to ce-PET/CT. However, radiotherapy fields were changed due to the results from ce-PET/CT in 23% of cases compared to CT or PET results alone. CONCLUSIONS: ce-PET/CT is superior to PET or CT alone for staging of anal cancer, with significant impact on therapy planning. |
| | |
Authors:
|
Peter Bannas; Christoph Weber; Gerhard Adam; Thorsten Frenzel; Thorsten Derlin; Janos Mester; Susanne Klutmann |
Publication Detail:
|
Type: Journal Article Date: 2010-09-09 |
Journal Detail:
|
Title: International journal of radiation oncology, biology, physics Volume: 81 ISSN: 1879-355X ISO Abbreviation: Int. J. Radiat. Oncol. Biol. Phys. Publication Date: 2011 Oct |
Date Detail:
|
Created Date: 2011-08-29 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7603616 Medline TA: Int J Radiat Oncol Biol Phys Country: United States |
Other Details:
|
Languages: eng Pagination: 445-51 Citation Subset: IM |
Copyright Information:
|
Copyright © 2011 Elsevier Inc. All rights reserved. |
Affiliation:
|
Department of Diagnostic and Interventional Radiology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Multi-Institutional Phase II Study of Proton Beam Therapy for Organ-Confined Prostate Cancer Focusin...
Next Document: Quality of life after whole pelvic versus prostate-only external beam radiotherapy for prostate canc...